Browse All

Current Filters

CLEAR FILTER x

TITLE

Effects of Semaglutide on Alzheimer’s Disease-related Biological Processes: Results from a Biofluid Biomarker and Multiomics Immunophenotyping Phase 3 Study in Patients with Early Alzheimer’s Disease After 12 Weeks of Treatment

Semaglutide Concentration in Cerebrospinal Fluid from Patients with Early Alzheimer’s Disease After 12 Weeks of Subcutaneous Treatment

Semaglutide Impacts Proteomic Signatures Related to Dementia Risk in the SELECT Cardiovascular Outcomes Trial